Zymeworks (ZYME)

• Market cap: $1.48B
• 1 day: 9.03%
• 5 days: 8.13%
• 1 month: 8.67%
• 3 months: 58.2%
• 6 months: 63.73%
• Year to date: 33.15%
• 1 year: 13.56%
• 5 years: -51.86%
• 10 years: 51.38%
• Sector: Healthcare
• Industry: Biotechnology

About: Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Employees: 273